Predicting disease progression more effectively and developing individual therapies
In some of its study centers the KKNMS is looking for participants for a long-term study that investigates which patients benefit from certain forms of treatment in early stages of MS. This so-called MS cohort study with 1000 participants is planned for a duration of 10 years. A total of 18 MS centers from all over Germany are involved in this research project.
Inclusion criteria:
- At least 18 years of age
- Clinically isolated syndrome (CIS) within the past 6 months or early relapsing-remitting multiple sclerosis for at the most 2 years after initial symptoms
- No previous long-term treatment for MS
Exclusion criteria:
- Any factors which argue against MRT examinations (i.e. intolerance to contrast medium, cardiac pacemaker, claustrophobia, etc.)
- Primary progressive MS
Currently we are not recruiting participants for the MS cohort study.
Participating MS centers
Klinik für Neurologie, Universitätsklinikum Düsseldorf
Neurologische Klinik
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
PI: Prof. Dr. Orhan Aktas
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PIs Studienzentrum: Prof. Dr. Hans-Peter-Hartung und Prof. Dr. Orhan Aktas
Universitätsmedizin Mainz, Klinik für Neurologie
Klinik für Neurologie
3.2 Brain network patterns as prognostic and therapy response markers in multiple sclerosis (MSNetworks)
PI: Prof. Dr. Frauke Zipp
Co-Pis: Prof. Dr. Sergiu Groppa, Dr. Felix Lüssi
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Frauke Zipp
Klinik für Neurologie und klinische Neurophysiologie Universitätsklinikum Augsburg
Neurologische Klinik und klinische Neurophysiologie
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
Assoziiertes Mitglied: Dr. Antonios Bayas
Institut für Klinische Neuroimmunologie Klinikum der LMU München, Großhadern
Institut für Klinische Neuroimmunologie
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
PI: Prof. Dr. Tania Kümpfel
3.4 B-cells and antibody profiles (BIginMS)
PI: Prof. Dr. Edgar Meinl
Co-PI: Prof. Dr. Reinhard Hohlfeld
5.5 Improved assessment of disease phenotypes in multiple sclerosis models (PhenoModel)
PI: Prof. Dr. Martin Kerschensteiner
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Tania Kümpfel
Max-Planck-Institut für Psychiatrie
1.5 Biostatistical support and data analysis (Biostat)
Co-PI: Prof. Dr. Bertram Müller-Myhsok
4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
Co-PI: Prof. Dr. Bertram Müller-Myhsok
4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
Co-PI: Prof. Dr. Bertram Müller-Myhsok
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Frank Weber
Medizinische Hochschule Hannover, Klinik für Neurologie OE 7210
Neurologische Klinik
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Prof. Dr. Corinna Trebst
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Martin Stangel
Universitätsklinikum Marburg, Klinik und Poliklinik für Neurologie
Central Information Office:
1.2 IT platform for the Competence Network Multiple Sclerosis (CoreUnitIT)
PI: Dr. Gisela Antony
2.1 Prospective cohort study in clinically isolated syndrome and early multiple sclerosis (KKNMS-Kohorte)
Co-PI: Dr. Gisela Antony
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Dr. Gisela Antony
2.4 Extension and internationalization of REGIMS, an immune therapy register for the improvement of drug safety and treatment of patients with MS (REGIMS)
Co-PI: Dr. Gisela Antony
Universitätsklinikum Marburg, Klinik für Neurologie:
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: PD Dr. Björn Tackenberg
St. Josef Hospital, Klinikum der Ruhr-Universität Bochum, Klinik für Neurologie
Neurologische Universitätsklinik:
2.1 Prospective cohort study in clinically isolated syndrome and early multiple sclerosis (KKNMS-Kohorte)
PI: Prof. Dr. Ralf Gold
Co-PI: Dr. Anke Salmen
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PIs: PD Dr. Kerstin Hellwig, Prof. Dr. Ingo Kleiter
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Ralf Gold
Institut für diagnostische und interventionelle Radiologie und Nuklearmedizin:
1.6 MRI Quality and Standards (MuSIQC)
PI: Prof. Dr. Carsten Lukas
4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
Co-PI: Prof. Dr. Carsten Lukas
Klinikum rechts der Isar der Technischen Universität München, Neurologische Klinik und Poliklinik
Klinikum rechts der Isar
Klinik und Poliklinik für Neurologie
1.1 Central Network Coordination (CoreOffice)
PI: Claudia Borsanyi
1.3 Biomaterial Bank of the KKNMS (Biobank)
PI: Prof. Dr. med. Bernhard Hemmer
4.2 Genetic determinants of MRI changes in MS (Gene-MRI)
PI: Prof. Dr. Mark Mühlau
4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
PI: Prof. Dr. Bernhard Hemmer
Co-PIs: Dr. Dorothea Buck
5.2 Interplay of antigen specific T cells and B cells in mouse models of neuromyelitis optica (T-B in NMO)
PI: Prof. Dr. Thomas Korn
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Bernhard Hemmer
Molekulare Neuroimmunologie, Neurologische Klinik, Universitätsklinikum Heidelberg
Neurologische Klinik
Sektion Molekulare Neuroimmunologie
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Prof. Dr. Brigitte Wildemann
3.5 Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (ProgramMS)
Co-PI: Prof. Dr. Brigitte Wildemann
3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
PI: Prof. Dr. Brigitte Wildemann
Co-PI: Dr. Jürgen Haas
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Brigitte Wildemann
Klinik und Poliklinik für Neurologie der Universität Ulm
Neurologische Universitätsklinik
3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
Co-PI: Prof. Dr. Hayrettin Tumani
4.3 Genetic determinants of cerebrospinal fluid parameters in multiple sclerosis (Gene-CSF)
Co-PI: Prof. Dr. Hayrettin Tumani
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Hayrettin Tumani
Charité – Universitätsmedizin Berlin
Institut für Neuroimmunologie
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Friedemann Paul
Universitätsklinikum Erlangen
Neurologische Klinik
Neuroimmunologie
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Ralf Linker
Institut für Neuroimmunologie und Multiple Sklerose (UKE)
Molekulare Neurobiologie Hamburg (ZMNH)
Institut für Neuroimmunologie und Multiple Sklerose (INIMS)
2.2 Comparing and Contrasting Multiple Sclerosis and Neuromyelitis optica Spectrum Disorders (NEMOS)
Co-PI: Dr. Jan-Patrick Stellmann
5.3 Modeling CD8+ T cell responses in multiple sclerosis (CD8Model)
PI: Prof. Dr. Manuel Friese
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Christoph Heesen
Klinik und Poliklinik für Neurologie, Universität Leipzig
Klinik und Poliklinik für Neurologie
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: PD Dr. Florian Then Bergh
Neurologische Poliklinik der Universität Rostock
Klinik für Neurologie und Poliklinik
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Uwe Zettl
Universitätsklinikum Tübingen, Zentrum für Neurologie, Hertie-Institut für klinische Hirnforschung, Abteilung Neurologie mit Schwerpunkt neurovaskuläre Erkrankungen
Allgemeine Neurologie
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. Ulf Ziemann
Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster
Universitätsklinikum – Department für Neurologie:
1.3 Biomaterial Bank of the KKNMS (Biobank)
Co-PI: Prof. Dr. Heinz Wiendl
3.1 Multi-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors (ImmuneMS)
PI: Prof. Dr. Heinz Wiendl
Co-PIs: Prof. Dr. Luisa Klotz; Dr. Catharina Groß
3.5 Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response (ProgramMS)
PI: Prof. Dr. Dr. Sven Meuth
Co-PIs: Prof. Dr. Heinz Wiendl, Dr. Tobias Ruck
3.6 Predictive markers of imminent recurrence or rebound disease activity in MS patients switching immunotherapy (ReboundMS)
Co-PIs: Prof. Dr. Heinz Wiendl, Prof. Dr. Dr. Sven Meuth
Studienzentrum der KKNMS-Kohorte (Projekt 2.1)
PI Studienzentrum: Prof. Dr. med. Heinz Wiendl
Institut für Epidemiologie und Sozialmedizin:
2.4 Extension and internationalization of REGIMS, an immune therapy register for the improvement of drug safety and treatment of patients with MS (REGIMS)
PI: Prof. Dr. Klaus Berger